ArticleBMC nephrology2025
Immunomodulatory effect of CD71
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundImmune abnormalities play a critical role in the pathogenesis of kidney failure. CD71
methodsPBMCs were isolated from 49 kidney failure patients and 20 healthy subjects. The frequencies of T cell subsets and CD71 + erythroid cells were determined by flow cytometry. The numbers of reticulocytes and RBCs were also measured. Panel-reactive antibodies screening was used to assess antibodies against human leukocyte antigens (HLAs) in the patients. The effect of CD71 + erythroid cells on PBMC proliferation in kidney failure patients was investigated using a CFSE labeling assay. Erythropoietin level was measured by ELISA.
resultsKidney failure patients showed a significant increase in CD71 + erythroid cells (P < 0.01). In contrast, the frequencies of Th1, Th2, and Th17 cells were significantly reduced in these patients (P < 0.01-0.05). Among CD4 + T subsets, Th1 cell frequency was inversely correlated with the number of CD71 + erythroid cells (P < 0.05). In vitro, CD71 + erythroid cells inhibited the proliferation of PMBCs in kidney failure patients (P < 0.0001-0.05). No significant difference was observed in Treg frequencies between patients and controls. The frequency of CD71 + erythroid cells was significantly decreased in kidney failure patients with anti-HLA antibodies, unlike patients without anti-HLA antibodies (P < 0.001). The patients had an increased number of reticulocytes, unlike RBC, in peripheral blood compared with healthy subjects (P < 0.01-0.05). The patients exhibited a reduction in erythropoietin level compared with the control group (P < 0.0001).
conclusionThese findings suggest CD71 + erythroid cells may contribute to immune dysregulation in kidney failure patients, potentially playing a role in disease progression and its immunopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.